Literature DB >> 2862891

Pharmacological experiments in healthy volunteers with bopindolol, a long-acting beta-adrenoceptor blocking drug with partial agonist activity.

W H Aellig.   

Abstract

Bopindolol is a potent and specific beta-adrenoceptor antagonist with partial agonist activity. In animal experiments it blocks both beta 1- and beta 2-adrenoceptors and possesses a long duration of action. In the present study in healthy volunteers bopindolol was about ten times more potent than pindolol in reducing isoprenaline-induced and exercise-induced tachycardia. In experiments on exercise-induced tachycardia an oral dose of 2 mg produced a near maximum reduction of exercise heart rate, occurring within 2 to 3 h of administration. With higher doses (up to 12 mg) the maximum effect was reached earlier (between 1 and 2 h). The long duration of action of bopindolol observed in animal studies was confirmed in man. Twenty-four hours after 4 and 10 mg bopindolol more than 2/3 of the maximum effect was still present. After 48 h 38% of the maximum effect of 4 mg and 50% of that of 12 mg remained. Even at 72 and 96 h exercise-induced tachycardia was still significantly lowered after both doses of the drug. When bopindolol was administered once daily for 5 days there was a slight increase in the maximum reduction of exercise-induced tachycardia during treatment with 1 mg/day but not with 4 mg/day, which produced a near maximum effect.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862891      PMCID: PMC1463880          DOI: 10.1111/j.1365-2125.1985.tb02713.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Concentration-effect relationships with FM 24: a new long acting beta-adrenergic receptor antagonist.

Authors:  C T Dollery; H J Dargie; J Sassard; G Cuisinaud
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

2.  Proceedings: Pharmacological studies with LL 21-945, a new beta-adrenoceptor blocking agent with a long duration of action.

Authors:  B J Clark; K Saameli; F Troxler
Journal:  Br J Pharmacol       Date:  1974-09       Impact factor: 8.739

3.  Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension.

Authors:  P van Brummelen; F R Bühler; F W Amann; P Bolli
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Simultaneous modeling of bopindolol kinetics and dynamics.

Authors:  R Platzer; R L Galeazzi; W Niederberger; J Rosenthaler
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

5.  beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

6.  Bopindolol: a new long acting beta-receptor antagonist; its effects on haemodynamics, and on the renin response to tilting.

Authors:  D R Turner; F J Goodwin; A R Knight; D W Littlejohns; V L Sharman; D W Vere
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Drug defaulting in a general practice.

Authors:  A M Porter
Journal:  Br Med J       Date:  1969-01-25

8.  Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age.

Authors:  U L Hulthén; P van Brummelen; F W Amann; F R Bühler
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

  8 in total
  6 in total

1.  The effect of density on the gastric emptying of single- and multiple-unit dosage forms.

Authors:  S S Davis; A F Stockwell; M J Taylor; J G Hardy; D R Whalley; C G Wilson; H Bechgaard; F N Christensen
Journal:  Pharm Res       Date:  1986-08       Impact factor: 4.200

2.  Bopindolol in chronic stable angina pectoris: duration and extent of antianginal action.

Authors:  G P Carboni; A B Scardovi; M D'Ermo; P L Prati
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

3.  The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.

Authors:  N J MacDonald; A C Grant; R S Rodger; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 4.  Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  D W Harron; K L Goa; H D Langtry
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.

Authors:  W H Aellig; E Nüesch; G Engel; J Grevel; W Niederberger; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

6.  Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.

Authors:  G Wensing; R A Branch; H Humbert; E E Ohnhaus; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.